A meta-analysis of 8 treatment trials (n=762) has concluded that a combination of an antidepressant with an antipsychotic agent is better than either alone in the treatment of psychotic depression (Farahani & Correll. J Clin Psychiatry 2012;73:486-496).
Latest News
Botulinum toxin type A may be effective for trigeminal neuralgia
November 7, 2012About two-thirds of patients with trigeminal neuralgia (TN) may respond to injections of botulinum toxin type A (BTX-A), according to the results of a double-blind, placebo-controlled trial (Wu et al. Cephalalgia 2012;32:443-450).
Dopamine agonist withdrawal syndrome: Canadian study results
October 24, 2012A new Canadian study reports that dopamine agonist withdrawal syndrome (DAWS) is a potentially disabling complication associated with dopamine agonist use in patients with Parkinson’s disease (Pondal et al. J Neurol Neurosurg Psychiatry 2012; epublished August 29, 2012).
Aubade for Aubagio: FDA approves teriflunomide in RRMS
October 24, 2012The U.S. Food and Drug Administration has approved the use of oral teriflunomide (Aubagio) 7 or 14 mg/day for the treatment of relapsing forms of MS. The drug was submitted for FDA review in October 2011. The drug has not yet been approved by Health Canada.